Other Species / Isoforms
  SKA3 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K10-ub
PIRSFCGkLRSLAST
0 1
SKA3 (human) PIRSFCGkLRSLAST K10-ub
SKA3 iso3 (human) PIRSFCGKLRSLAST K10
SKA3 (mouse) PIQSFHCKLRGLATT K10
SKA3 (rat) PIQSFHCKLRSLATV K10
S34-p
RALDGEEsDFEDyPM
0 7
SKA3 (human) RALDGEEsDFEDyPM S34-p
SKA3 iso3 (human) RALDGEESDFEDYPM S34
SKA3 (mouse) RALDGEDSDFEDSPG S34
SKA3 (rat) RALDGEDSDFEDSSA S34
Y39-p
EEsDFEDyPMRILyD
0 2
SKA3 (human) EEsDFEDyPMRILyD Y39-p
SKA3 iso3 (human) EESDFEDYPMRILYD Y39
SKA3 (mouse) EDSDFEDSPGRILHD S39
SKA3 (rat) EDSDFEDSSARILCD S39
Y45-p
DyPMRILyDLHSEVQ
0 1
SKA3 (human) DyPMRILyDLHSEVQ Y45-p
SKA3 iso3 (human) DYPMRILYDLHSEVQ Y45
SKA3 (mouse) DSPGRILHDLHSEVQ H45
SKA3 (rat) DSSARILCDLYSEVQ C45
K64-ac
DVNILLDkARLENQE
0 1
SKA3 (human) DVNILLDkARLENQE K64-ac
SKA3 iso3 (human) DVNILLDKARLENQE K64
SKA3 (mouse) NVNALLDEARLENQE E64
SKA3 (rat) DVNAHLDKARLESRE K64
K64-ub
DVNILLDkARLENQE
0 1
SKA3 (human) DVNILLDkARLENQE K64-ub
SKA3 iso3 (human) DVNILLDKARLENQE K64
SKA3 (mouse) NVNALLDEARLENQE E64
SKA3 (rat) DVNAHLDKARLESRE K64
K77-ub
QEGIDFIkATKVLME
0 1
SKA3 (human) QEGIDFIkATKVLME K77-ub
SKA3 iso3 (human) QEGIDFIKATKVLME K77
SKA3 (mouse) QESTRFKKAtKILME K77
SKA3 (rat) RESTHFIKAAKVLMK K77
T79
GIDFIkATKVLMEKN
0 1
SKA3 (human) GIDFIkATKVLMEKN T79
SKA3 iso3 (human) GIDFIKATKVLMEKN T79
SKA3 (mouse) STRFKKAtKILMEKN T79-p
SKA3 (rat) STHFIKAAKVLMKKN A79
S87-p
KVLMEKNsMDIMKIR
0 1
SKA3 (human) KVLMEKNsMDIMKIR S87-p
SKA3 iso3 (human) KVLMEKNSMDIMKIR S87
SKA3 (mouse) KILMEKNSADVRKLR S87
SKA3 (rat) KVLMKKNSADIIKLR S87
K99-ub
KIREYFQkyGysPRV
0 3
SKA3 (human) KIREYFQkyGysPRV K99-ub
SKA3 iso3 (human) KIREYFQKYGYSPRV K99
SKA3 (mouse) KLREFFQKYGYQARD K99
SKA3 (rat) KLREFFQKYGYQARD K99
Y100-p
IREYFQkyGysPRVK
0 1
SKA3 (human) IREYFQkyGysPRVK Y100-p
SKA3 iso3 (human) IREYFQKYGYSPRVK Y100
SKA3 (mouse) LREFFQKYGYQARDK Y100
SKA3 (rat) LREFFQKYGYQARDK Y100
Y102-p
EYFQkyGysPRVKkN
0 1
SKA3 (human) EYFQkyGysPRVKkN Y102-p
SKA3 iso3 (human) EYFQKYGYSPRVKKN Y102
SKA3 (mouse) EFFQKYGYQARDKED Y102
SKA3 (rat) EFFQKYGYQARDKED Y102
S103-p
YFQkyGysPRVKkNs
0 7
SKA3 (human) YFQkyGysPRVKkNs S103-p
SKA3 iso3 (human) YFQKYGYSPRVKKNS S103
SKA3 (mouse) FFQKYGYQARDKEDS Q103
SKA3 (rat) FFQKYGYQARDKEDS Q103
K108-ub
GysPRVKkNsVHEQE
0 1
SKA3 (human) GysPRVKkNsVHEQE K108-ub
SKA3 iso3 (human) GYSPRVKKNSVHEQE K108
SKA3 (mouse) GYQARDKEDSGCEHR E108
SKA3 (rat) GYQARDKEDSACEHR E108
S110-p
sPRVKkNsVHEQEAI
Upstream
0 16
Treatment
  • vemurafenib
SKA3 (human) sPRVKkNsVHEQEAI S110-p
SKA3 iso3 (human) SPRVKKNSVHEQEAI S110
SKA3 (mouse) QARDKEDSGCEHRVN S110
SKA3 (rat) QARDKEDSACEHRVS S110
S119-p
HEQEAINsDPELsNC
Upstream
0 27
Treatment
  • metformin
  • vemurafenib
SKA3 (human) HEQEAINsDPELsNC S119-p
SKA3 iso3 (human) HEQEAINSDPELSNC S119
SKA3 (mouse) CEHRVNNStPELAVC S119
SKA3 (rat) CEHRVSNSSPGLAVC S119
D120
EQEAINsDPELsNCE
0 2
SKA3 (human) EQEAINsDPELsNCE D120
SKA3 iso3 (human) EQEAINSDPELSNCE D120
SKA3 (mouse) EHRVNNStPELAVCK T120-p
SKA3 (rat) EHRVSNSSPGLAVCK S120
S124-p
INsDPELsNCENFQk
0 2
SKA3 (human) INsDPELsNCENFQk S124-p
SKA3 iso3 (human) INSDPELSNCENFQK S124
SKA3 (mouse) NNStPELAVCKDIQK A124
SKA3 (rat) SNSSPGLAVCKDTQE A124
K131-ub
sNCENFQktDVKDDL
0 1
SKA3 (human) sNCENFQktDVKDDL K131-ub
SKA3 iso3 (human) SNCENFQKTDVKDDL K131
SKA3 (mouse) AVCKDIQKAGVKELs K131
SKA3 (rat) AVCKDTQEPGVKQEL E131
T132-p
NCENFQktDVKDDLs
0 1
SKA3 (human) NCENFQktDVKDDLs T132-p
SKA3 iso3 (human) NCENFQKTDVKDDLS T132
SKA3 (mouse) VCKDIQKAGVKELsD A132
SKA3 (rat) VCKDTQEPGVKQELS P132
S139-p
tDVKDDLsDPPVASs
0 4
SKA3 (human) tDVKDDLsDPPVASs S139-p
SKA3 iso3 (human) TDVKDDLSDPPVASS S139
SKA3 (mouse) KAGVKELsDPCVPSG S138-p
SKA3 (rat) PGVKQELSEPRVPRG S139
S146-p
sDPPVASsCIsEksP
0 2
SKA3 (human) sDPPVASsCIsEksP S146-p
SKA3 iso3 (human) SDPPVASSCISEKSP S146
SKA3 (mouse) sDPCVPSGsVsEEPL G145
SKA3 (rat) SEPRVPRGSAPEEPL G146
C147
DPPVASsCIsEksPR
0 1
SKA3 (human) DPPVASsCIsEksPR C147
SKA3 iso3 (human) DPPVASSCISEKSPR C147
SKA3 (mouse) DPCVPSGsVsEEPLR S146-p
SKA3 (rat) EPRVPRGSAPEEPLR S147
S149-p
PVASsCIsEksPRsP
0 2
SKA3 (human) PVASsCIsEksPRsP S149-p
SKA3 iso3 (human) PVASSCISEKSPRSP S149
SKA3 (mouse) CVPSGsVsEEPLRsP S148-p
SKA3 (rat) RVPRGSAPEEPLRSP P149
K151-ub
ASsCIsEksPRsPQL
0 2
SKA3 (human) ASsCIsEksPRsPQL K151-ub
SKA3 iso3 (human) ASSCISEKSPRSPQL K151
SKA3 (mouse) PSGsVsEEPLRsPQL E150
SKA3 (rat) PRGSAPEEPLRSPQL E151
S152-p
SsCIsEksPRsPQLs
Upstream
0 20
Treatment
  • angiotensin_2
  • nocodazole
SKA3 (human) SsCIsEksPRsPQLs S152-p
SKA3 iso3 (human) SSCISEKSPRSPQLS S152
SKA3 (mouse) SGsVsEEPLRsPQLs P151
SKA3 (rat) RGSAPEEPLRSPQLS P152
S155-p
IsEksPRsPQLsDFG
Upstream
0 81
Treatment
  • angiotensin_2
  • antibody
  • metastatic potential
  • nocodazole
view more >
SKA3 (human) IsEksPRsPQLsDFG S155-p
SKA3 iso3 (human) ISEKSPRSPQLSDFG S155
SKA3 (mouse) VsEEPLRsPQLsDFG S154-p
SKA3 (rat) APEEPLRSPQLSDFG S155
S159-p
sPRsPQLsDFGLERy
0 7
SKA3 (human) sPRsPQLsDFGLERy S159-p
SKA3 iso3 (human) SPRSPQLSDFGLERY S159
SKA3 (mouse) PLRsPQLsDFGLQRy S158-p
SKA3 (rat) PLRSPQLSDFGLQRY S159
Y166-p
sDFGLERyIVSQVLP
0 2
SKA3 (human) sDFGLERyIVSQVLP Y166-p
SKA3 iso3 (human) SDFGLERYIVSQVLP Y166
SKA3 (mouse) sDFGLQRyIIsQVPA Y165-p
SKA3 (rat) SDFGLQRYMVSQGPA Y166
S169
GLERyIVSQVLPNPP
0 1
SKA3 (human) GLERyIVSQVLPNPP S169
SKA3 iso3 (human) GLERYIVSQVLPNPP S169
SKA3 (mouse) GLQRyIIsQVPANPP S168-p
SKA3 (rat) GLQRYMVSQGPANPR S169
K183-ub
PQAVNNYkEEPVIVt
0 1
SKA3 (human) PQAVNNYkEEPVIVt K183-ub
SKA3 iso3 (human) PQAVNNYKEEPVIVT K183
SKA3 (mouse) PQTAASLKEERVAEt K182
SKA3 (rat) RQETVSLKEDRASET K183
T190-p
kEEPVIVtPPTkQsL
0 13
SKA3 (human) kEEPVIVtPPTkQsL T190-p
SKA3 iso3 (human) KEEPVIVTPPTKQSL T190
SKA3 (mouse) KEERVAEtPPAKDPS T189-p
SKA3 (rat) KEDRASETTPAKDPS T190
K194-ub
VIVtPPTkQsLVkVL
0 1
SKA3 (human) VIVtPPTkQsLVkVL K194-ub
SKA3 iso3 (human) VIVTPPTKQSLVKVL K194
SKA3 (mouse) VAEtPPAKDPSVQVL K193
SKA3 (rat) ASETTPAKDPSVQVL K194
S196-p
VtPPTkQsLVkVLKt
0 2
SKA3 (human) VtPPTkQsLVkVLKt S196-p
SKA3 iso3 (human) VTPPTKQSLVKVLKT S196
SKA3 (mouse) EtPPAKDPSVQVLKT P195
SKA3 (rat) ETTPAKDPSVQVLKT P196
K199-ub
PTkQsLVkVLKtPKC
0 2
SKA3 (human) PTkQsLVkVLKtPKC K199-ub
SKA3 iso3 (human) PTKQSLVKVLKTPKC K199
SKA3 (mouse) PAKDPSVQVLKTPRC Q198
SKA3 (rat) PAKDPSVQVLKTPRC Q199
T203-p
sLVkVLKtPKCALkM
Upstream
Downstream
1 1
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
SKA3 (human) sLVkVLKtPKCALkM T203-p
SKA3 iso3 (human) SLVKVLKTPKCALKM T203
SKA3 (mouse) PSVQVLKTPRCALRM T202
SKA3 (rat) PSVQVLKTPRCALKM T203
K209-ub
KtPKCALkMDDFECV
0 1
SKA3 (human) KtPKCALkMDDFECV K209-ub
SKA3 iso3 (human) KTPKCALKMDDFECV K209
SKA3 (mouse) KTPRCALRMDDFECE R208
SKA3 (rat) KTPRCALKMDDFECV K209
T217-p
MDDFECVtPKLEHFG
Upstream
Downstream
1 8
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
SKA3 (human) MDDFECVtPKLEHFG T217-p
SKA3 iso3 (human) MDDFECVTPKLEHFG T217
SKA3 (mouse) MDDFECETPKLEHFG T216
SKA3 (rat) MDDFECVTPKLEHFG T217
Y228-p
EHFGISEytMCLNED
0 6
SKA3 (human) EHFGISEytMCLNED Y228-p
SKA3 iso3 (human) EHFGISEYTMCLNED Y228
SKA3 (mouse) EHFGISEHTMCLNED H227
SKA3 (rat) EHFGISEYTMCLNED Y228
T229-p
HFGISEytMCLNEDy
0 1
SKA3 (human) HFGISEytMCLNEDy T229-p
SKA3 iso3 (human) HFGISEYTMCLNEDY T229
SKA3 (mouse) HFGISEHTMCLNEDY T228
SKA3 (rat) HFGISEYTMCLNEDY T229
Y236-p
tMCLNEDyTMGLKNA
0 15
SKA3 (human) tMCLNEDyTMGLKNA Y236-p
SKA3 iso3 (human) TMCLNEDYTMGLKNA Y236
SKA3 (mouse) TMCLNEDYTMGLKNM Y235
SKA3 (rat) TMCLNEDYTMGLKNM Y236
K247-ub
LKNARNNksEEAIDT
0 1
SKA3 (human) LKNARNNksEEAIDT K247-ub
SKA3 iso3 (human) LKNARNNKSEEAIDT K247
SKA3 (mouse) LKNMKNIKSSLLSGV K246
SKA3 (rat) LKNMKSIKSSPLSGV K247
S248-p
KNARNNksEEAIDTE
0 4
SKA3 (human) KNARNNksEEAIDTE S248-p
SKA3 iso3 (human) KNARNNKSEEAIDTE S248
SKA3 (mouse) KNMKNIKSSLLSGVS S247
SKA3 (rat) KNMKSIKSSPLSGVG S248
T265-p
LNDNVFAtPsPIIQQ
Upstream
0 11
Treatment
  • nocodazole
SKA3 (human) LNDNVFAtPsPIIQQ T265-p
SKA3 iso3 (human) LNDNVFATPSPIIQQ T265
SKA3 (mouse) TSDNSFAIPGPIIQQ I271
SKA3 (rat) TSDNSFAIPGPMIQQ I272
S267-p
DNVFAtPsPIIQQLE
Upstream
0 12
Treatment
  • nocodazole
SKA3 (human) DNVFAtPsPIIQQLE S267-p
SKA3 iso3 (human) DNVFATPSPIIQQLE S267
SKA3 (mouse) DNSFAIPGPIIQQME G273
SKA3 (rat) DNSFAIPGPMIQQLE G274
K275-ub
PIIQQLEksDAEytN
0 1
SKA3 (human) PIIQQLEksDAEytN K275-ub
SKA3 iso3 (human) PIIQQLEKSDAEYTN K275
SKA3 (mouse) PIIQQMEENDVEYVS E281
SKA3 (rat) PMIQQLEKNDVEYIN K282
S276-p
IIQQLEksDAEytNs
0 4
SKA3 (human) IIQQLEksDAEytNs S276-p
SKA3 iso3 (human) IIQQLEKSDAEYTNS S276
SKA3 (mouse) IIQQMEENDVEYVSS N282
SKA3 (rat) MIQQLEKNDVEYINS N283
Y280-p
LEksDAEytNsPLVP
0 12
SKA3 (human) LEksDAEytNsPLVP Y280-p
SKA3 iso3 (human) LEKSDAEYTNSPLVP Y280
SKA3 (mouse) MEENDVEYVSSPLPP Y286
SKA3 (rat) LEKNDVEYINSPLPP Y287
T281-p
EksDAEytNsPLVPT
0 2
SKA3 (human) EksDAEytNsPLVPT T281-p
SKA3 iso3 (human) EKSDAEYTNSPLVPT T281
SKA3 (mouse) EENDVEYVSSPLPPK V287
SKA3 (rat) EKNDVEYINSPLPPK I288
S283-p
sDAEytNsPLVPTFC
Upstream
Downstream
1 4
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
SKA3 (human) sDAEytNsPLVPTFC S283-p
SKA3 iso3 (human) SDAEYTNSPLVPTFC S283
SKA3 (mouse) NDVEYVSSPLPPKFC S289
SKA3 (rat) NDVEYINSPLPPKFC S290
T291-p
PLVPTFCtPGLkIPS
Upstream
Downstream
1 4
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
SKA3 (human) PLVPTFCtPGLkIPS T291-p
SKA3 iso3 (human) PLVPTFCTPGLKIPS T291
SKA3 (mouse) PLPPKFCTPGLKIPS T297
SKA3 (rat) PLPPKFCTPGLKIPS T298
K295-ub
TFCtPGLkIPSTkNs
0 1
SKA3 (human) TFCtPGLkIPSTkNs K295-ub
SKA3 iso3 (human) TFCTPGLKIPSTKNS K295
SKA3 (mouse) KFCTPGLKIPSTMDR K301
SKA3 (rat) KFCTPGLKIPSSMDS K302
K300-ub
GLkIPSTkNsIALVs
0 2
SKA3 (human) GLkIPSTkNsIALVs K300-ub
SKA3 iso3 (human) GLKIPSTKNSIALVS K300
SKA3 (mouse) GLKIPSTMDRTDLVS M306
SKA3 (rat) GLKIPSSMDSTDLVS M307
S302-p
kIPSTkNsIALVsTN
0 1
SKA3 (human) kIPSTkNsIALVsTN S302-p
SKA3 iso3 (human) KIPSTKNSIALVSTN S302
SKA3 (mouse) KIPSTMDRTDLVSID R308
SKA3 (rat) KIPSSMDSTDLVSID S309
S307-p
kNsIALVsTNyPLsk
0 1
SKA3 (human) kNsIALVsTNyPLsk S307-p
SKA3 iso3 (human) KNSIALVSTNYPLSK S307
SKA3 (mouse) MDRTDLVSIDYPLSK S313
SKA3 (rat) MDSTDLVSIDYPLSK S314
Y310-p
IALVsTNyPLskTNs
0 19
SKA3 (human) IALVsTNyPLskTNs Y310-p
SKA3 iso3 (human) IALVSTNYPLSKTNS Y310
SKA3 (mouse) TDLVSIDYPLSKPNS Y316
SKA3 (rat) TDLVSIDYPLSKPNS Y317
S313-p
VsTNyPLskTNsssN
0 3
SKA3 (human) VsTNyPLskTNsssN S313-p
SKA3 iso3 (human) VSTNYPLSKTNSSSN S313
SKA3 (mouse) VSIDYPLSKPNSsST S319
SKA3 (rat) VSIDYPLSKPNSSPT S320
K314-ub
sTNyPLskTNsssND
0 2
SKA3 (human) sTNyPLskTNsssND K314-ub
SKA3 iso3 (human) STNYPLSKTNSSSND K314
SKA3 (mouse) SIDYPLSKPNSsSTD K320
SKA3 (rat) SIDYPLSKPNSSPTD K321
S317-p
yPLskTNsssNDLEV
Upstream
0 5
Regulatory protein:
  • PLK1 (human)
Treatment
  • ischemia
SKA3 (human) yPLskTNsssNDLEV S317-p
SKA3 iso3 (human) YPLSKTNSSSNDLEV S317
SKA3 (mouse) YPLSKPNSsSTDLEI S323
SKA3 (rat) YPLSKPNSSPTDLED S324
S318-p
PLskTNsssNDLEVE
0 8
SKA3 (human) PLskTNsssNDLEVE S318-p
SKA3 iso3 (human) PLSKTNSSSNDLEVE S318
SKA3 (mouse) PLSKPNSsSTDLEIK S324-p
SKA3 (rat) PLSKPNSSPTDLEDK S325
S319-p
LskTNsssNDLEVED
0 1
SKA3 (human) LskTNsssNDLEVED S319-p
SKA3 iso3 (human) LSKTNSSSNDLEVED S319
SKA3 (mouse) LSKPNSsSTDLEIKD S325
SKA3 (rat) LSKPNSSPTDLEDKD P326
T358-p
SYENLLRtPtPPEVT
Upstream
Downstream
2 12
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
Putative in vivo kinases:
  • CDK1 (human)
SKA3 (human) SYENLLRtPtPPEVT T358-p
SKA3 iso3 (human) SYENLLRTPTPPEVT T358
SKA3 (mouse) TSCENFATPSPPKVT T363
SKA3 (rat) TSYENFTTPSPPKVT T364
T360-p
ENLLRtPtPPEVTkI
Upstream
Downstream
3 18
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
  • cell growth, induced
  • chromatin organization, altered
  • cytoskeletal reorganization
Kinase, in vitro:
  • CDK1 (human)
Putative in vivo kinases:
  • CDK1 (human)
SKA3 (human) ENLLRtPtPPEVTkI T360-p
SKA3 iso3 (human) ENLLRTPTPPEVTkI T360
SKA3 (mouse) CENFATPSPPKVTAI S365
SKA3 (rat) YENFTTPSPPKVTAI S366
K366-ub
PtPPEVTkIPEDILQ
0 5
SKA3 (human) PtPPEVTkIPEDILQ K366-ub
SKA3 iso3 (human) PTPPEVTkIPEDILQ K366-ub
SKA3 (mouse) PSPPKVTAIPEDILQ A371
SKA3 (rat) PSPPKVTAIPEDILQ A372
T384-p
KYNSNLAtPIAIKAV
0 12
SKA3 (human) KYNSNLAtPIAIKAV T384-p
SKA3 iso3 (human) gap -
SKA3 (mouse) KHSSNLAsPLDVKVM S389-p
SKA3 (rat) KYNSNLASPIDVKAM S389
K399-ub
PPSKRFLkHGQNIRD
0 1
SKA3 (human) PPSKRFLkHGQNIRD K399-ub
SKA3 iso3 (human) gap -
SKA3 (mouse) gap -
SKA3 (rat) PLRRGFTSKGQSTRG S404
S408-p
GQNIRDVsNKEN___
0 1
SKA3 (human) GQNIRDVsNKEN___ S408-p
SKA3 iso3 (human) gap -
SKA3 (mouse) RKGTRGAANKENW__ A406
SKA3 (rat) GQSTRGAANKENW__ A413